Abstract:PL02-02 Myeloid immune suppressor cells (MISCs), of myeloid macrophage/dendritic cell lineage, are significantly over-produced in the bone marrow and spleens of tumor-bearing mice as well as in peripheral blood of cancer patients. Interestingly, VEGF, the potent angiogenic factor and produced in most solid tumors, induces MISC production in vivo. In mice they express CD11b, a marker for myeloid cells of the macrophage lineage, and a marker for granulocytes, Gr-1. MISCs have been demonstrated to be immune suppressive since the 1980s. In this report, we demonstrate a novel tumor-promoting role of myeloid immune suppressor cells. These cells constitute 5% of total cells in solid tumors. Tumor cells coinjected with MISCs exhibited increased vascularization and decreased necrosis, as well as enhanced tumor growth. These immune cells produce high levels of MMP9. Deletion of MMP9 in these cells completely abolishes their tumor-promoting ability. MISCs were also found to directly incorporate into tumor endothelium. Consistent with this observation, MISCs acquire endothelial cell properties in tumor microenvironment and proangiogenic culture conditions. Furthermore, MISCs promote tumor metastasis through enhanced invasion. MISCs infiltrate into the invasive front with enhanced production and function of MMPs. Mice with 4T1 tumors co-injected with MISCs had significantly higher recurrent tumors at the injection site following surgical removal. 4T1 cells co-cultured with MISCs showed significantly increased invasion in vitro. Treatment with an MMP inhibitor significantly attenuated this process, suggesting a strong role of MISCs in tumor cell invasion through MMPs. In summary, MISCs are over-produced in tumor-bearing hosts, they can be re-programmed in multiple ways to promote tumor progression including angiogenesis, tumor growth and metastasis. Cellular and molecular targeting of MISC production should not only improve host immunosurveillance but also inhibit tumor metastasis, having the effect of “killing two birds with one stone.”

Data from MIF Produced by Bone Marrow–Derived Macrophages Contributes to Teratoma Progression after Embryonic Stem Cell Transplantation

Expansion of Myeloid Immune Suppressor Cells in Tumor-bearing Host Directly Promotes Tumor Angiogenesis, Tumor Growth, and Metastasis

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Intratumor Heterogeneity of MIF Expression Correlates with Extramedullary Involvement of Multiple Myeloma.

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure 3 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure S7 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure 8 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure S5 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure 6 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Supplementary Figure 5 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure S3 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure 7 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 4 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 6 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Figure 7 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis